The past decade has seen an increase in therapeutic options for Alzheimer's disease (AD) that target neurotransmitters, such as acetylcholine, and research continues to target abnormal proteins in the AD brain. Recently, glutamate excitotoxicity has also become a target for AD treatment with the advent of memantine. Clinical trial data reviewed for memantine show good tolerability, low side-effect profiles and a positive therapeutic impact in moderate-to-severe AD, both as monotherapy and in conjunction with donepezil. However, additional data suggest variable benefits in the mild stages of AD. Furthermore, published reports support reduced dosing in patients with significant renal disease. However, the opportunity to target a second mechanism in the treatment of AD, thereby providing added symptomatic benefit, appears to be a useful consideration for clinicians who treat this devastating neurodegenerative disorder.
|Number of pages||7|
|Journal||Expert Opinion on Drug Metabolism and Toxicology|
|State||Published - Feb 2007|
Bibliographical noteFunding Information:
This work was supported by National Institute on Aging grants P50 AG05144 and R01 AG19241.
- Alzheimer's disease
- Clinical trials
ASJC Scopus subject areas